Cabazitaxel in the Management of Metastatic Castration-resistant Prostate Cancer
327 investigators, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 2004;351:1502–12.
4. Petrylak DP, Tangen CM, Hussain MH, et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 2004; 351:1513–20.
5. Eymard JC, Oudard S, Gravis G, et al., Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study, BJU Int, 2010;106:974-8.
6. Sella A, Yarom N, Zisman A, et al., Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer, Oncology, 2009;76:442–6.
7. Dorff TB, Goldman B, Pinski JK, et al., Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer, Clin Cancer Res, 2010;16:3028–34.
8. de Bono JS, Oudard S, Ozguroglu M, et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration- resistant prostate cancer progressing after docetaxel
treatment: a randomised open-label trial, Lancet, 2010;376:1147–54.
9. de Bono JS, Logothetis CJ, Molina A, et al., Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 2011;364:1995–2005.
10. Aller AW, Kraus LA, Bissery M-C, In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract], Proc Am Assoc Cancer Res, 2000;41:303:Abstract #1923.
11. Bissery M-C, Bouchard H, Riou JF, et al., Preclinical evaluation of TXD258, a new taxoid [abstract], Proc Am Assoc Cancer Res, 2000;41:214:Abstract #1364.
12. Bouchet BP, Galmarini CM, Cabazitaxel, a new taxane with favorable properties, Drugs Today (Barc), 2010;46:735–42.
13. Cisternino S, Bourasset F, Archimbaud Y, et al., Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats, Br J Pharmacol, 2003;138:1367–75.
14. Mita AC, Denis LJ, Rowinsky EK, et al., Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors, Clin Cancer Res, 2009;15:723–30.
15. Pivot X, Koralewski P, Hidalgo JL, et al., A multicenter
phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients, Ann Oncol, 2008;19:1547–52.
16. Mottet N, Bellmunt J, Bolla M, et al., EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 2011;59:572–83.
17. Heidenreich A, Scholz HJ, van Oort I, et al., Cabazitaxel plus prednisone for patients with metastatic castration- resistant prostate cancer previously treated with a docetaxel-containing regimen: Interim analysis results from an ongoing compassionate-use programme, Presented at the ESMO/ECCO Congress, Stockholm, Sweden; September 23–27 2011: Abstract #7044.
18. Mezynski J, Pezaro C, Bianchini D, et al., Antitumor activity of docetaxel following treatment with the CYP17 inhibitor abiraterone acetate: clinical evidence for cross resistance? Presented at the ESMO/ECCO Congress, Stockholm, Sweden: September 23–27, 2011.
19. Pfister D, Epplen R, Piper C, Heidenreich A, Comparison of second-line treatments in patients with PSA relapse after or during docetaxel-chemotherapy, ASCO GU, San Francisco, US: February 2–4 2012, abstract.
EUROPEAN ONCOLOGY & HAEMATOLOGY
45
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77